Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donor Derived CD117 CAR-T Cells in R/R AML
NCT07144020Phase 1Recruiting
- Sponsor
- Zhejiang University
- Start
- Sep 2025
- Primary completion
- Sep 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD117 CAR-T cells in acute myeloid leukemia (AML), sponsored by Zhejiang University. Primary endpoints: Dose-limiting toxicity at 28 days and Treatment-emergent adverse events at 2 years. Started Sep 2025; status: recruiting.
02
Drugs
CD117 CAR-T cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07144020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07144020.